Article

An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s disease

2024-02-21

Abstract excerpt

<h4>ABSTRACT</h4> CT1812 is a novel, brain penetrant small molecule modulator of the sigma-2 receptor (S2R) that is currently in clinical development for the treatment of Alzheimer’s disease (AD). Preclinical and early clinical data show that, through S2R, CT1812 selectively prevents and displaces binding of amyloid beta (Aβ) oligomers from neuronal synapses and improves cognitive function in animal models of AD....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0b3f08a3-e6ce-5f7a-b768-bbe4a8f3cef9
DOI: 10.1101/2024.02.16.578765

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s diseaseDOI 10.1101/2024.02.16.578765Read

An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's diseaseSemantic proximity Read

CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's diseaseSemantic proximity Read

CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signaturesSemantic proximity Read

Small Molecule Agonists of TREM2 Reprogram Microglia and Protect Synapses in Human Alzheimer’s ModelsSemantic proximity Read

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsSemantic proximity Read

Dual Inhibitors Targeting G9a and GSK-3β: Translational Perspectives on Alzheimer’s Disease TreatmentSemantic proximity Read

Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design (P12-3.017)Semantic proximity Read

Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s DiseaseSemantic proximity Read

BT-11 repurposing potential for Alzheimer’s disease and insights into its mode of actionsSemantic proximity Read

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read

Multiplex plasma profiling of synaptic biomarkers in Alzheimer’s disease using NULISA: early alterations, APOE genotype effects, and pTau217 associationsSemantic proximity Read

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read